Real-World Experience in Extracorporeal Photopheresis for Adults with Graft-versus-Host Disease.

Extracorporeal photopheresis (ECP) has shown efficacy in treating graft-versus-host disease (GVHD). We aim to summarize eight years of real-world experience with off-line ECP in our institution, in order to validate this treatment schedule and analyze predictive factors. All consecutive adult patients with steroid-dependent or steroid-refractory GVHD undergoing off-line ECP were included in this single-center retrospective study. ECP was performed with a Spectra Optia device, processing 1 total blood volume, at a twice-weekly frequency for acute GVHD (aGVHD) and once weekly for chronic GVHD (cGVHD), and tapered individually according to clinical response. The cumulative incidence of response, including complete response (CR) and partial response (PR), were compared among patients grouped by different baseline, apheresis, and disease characteristics. Between January 2015 and May 2022, a total of 1382 ECP procedures were proposed for 82 patients. No incidents were reported in 97% of the ECP sessions. GVHD responded in 78% of patients (aGVHD: 57% CR and 4% PR; cGVHD, 39% CR and 48% PR). Overall survival was statistically greater for aGVHD patients who responded to ECP compared to those who did not respond (67.5% versus 26% at 1 year; P = 0.037). Severity was an independent predictor of response in aGVHD, whereas the absence of mouth involvement and lower lymphocyte counts in the apheresis product correlated with a higher response in cGVHD. Our findings support the effectiveness of this treatment schedule for GVHD. Further investigation is required to identify ECP-specific predictive factors, given that findings are not homogeneous across studies.

Extracorporeal Photopheresis in Graft-versus-Host Disease.

Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity following allogeneic hematopoietic stem cell transplantation. Extracorporeal photopheresis (ECP), which exposes mononuclear cells to ultraviolet A irradiation in the presence of a photosensitizing agent, has shown efficacy in the treatment of GVHD. Recent observations in molecular and cell biology have revealed the mechanisms by which ECP can reverse GVHD, including lymphocyte apoptosis, differentiation of dendritic cells from circulating monocytes, and modification of the cytokine profile and T cell subpopulations. Technical innovations have made ECP accessible to a broader range of patients; however, logistical constraints may limit its use. In this review, we scrutinize the development of ECP from its origins to recent insights into the biology underlying ECP efficacy. We also review practical aspects that may complicate successful ECP treatment. Finally, we analyze how these theoretical concepts translate into clinical practice, summarizing the published experiences of leading research groups worldwide.

Role of extracorporeal photopheresis in the management of children with graft-vs-host disease.

INTRODUCTION: Graft-vs-host disease (GVHD) is a frequent cause of morbidity and mortality in allogeneic stem cell transplants. Extracorporeal photopheresis (ECP) is one of the most accepted second-line treatments, but technical issues of ECP in children might be prohibitive. MATERIALS AND METHODS: Patients under 18 y of age with corticodependant or corticorefractory GVHD receiving ECP at our hospital were included in this retrospective study. ECP was performed with an in-line system (CellExTherakos) in 2013-2014 and with an off-line system (Spectra Optia) from 2015 onwards. Cumulative incidence curves were obtained to compare ECP efficacy among patients grouped by different baseline, apheresis, and disease characteristics. Significant variables on univariate analysis (Gray's test) were pooled into a multivariate analysis (Fine-Gray proportional hazard regression for competing events). RESULTS: A total of 701 ECP sessions were performed on 33 patients between October 2013 and December 2021. In total, 97% of the sessions could be executed. In 8% of the sessions an incident was detected, most of them mild and related to catheter dysfunction. With a median follow-up for alive patients of 33.6 mo (range, 8-95), the composite partial and complete response cumulative incidence was 70% (95% confidence interval, 51%-82%) and the median time to maximal response was 2.8 mo (range, 0.25-9.8). Significantly lower response ratios were found in patients with hepatic, gastrointestinal, acute, or severe GVHD. The only variable that influenced response on multivariate analysis was GVHD severity. DISCUSSION: ECP is feasible, safe, and effective for pediatric patients with corticorefractory or corticodependant GVHD, offering a less toxic and nonimmunosuppressive treatment option.

Platelet Transfusion: And Update on Challenges and Outcomes.

Platelet transfusion is a common practice in onco-hematologic patients for preventing or treating hemorrhages. Platelet concentrates can be transfused with therapeutic or prophylactic purposes. With the aim to help clinicians to take the decisions on platelet transfusion, some guidelines have been developed based on the current scientific evidence. However, there are some controversial issues and available scientific evidence is not enough to solve them. There is little information about what is the best platelet product to be transfused: random platelets or single donor apheresis platelets, and plasma-suspended or additive solution suspended platelets. Platelets are often transfused without respecting the ABO compatibility, but influence of this practice on platelet transfusion outcome is not well established. In the prophylactic platelet transfusion set there are some questions unsolved as the platelet threshold to transfuse prior to specific procedures or surgery, and even if platelet transfusion is necessary for some specific procedures as autologous hematopoietic stem cell transplantation. A challenging complication raised from multiple platelet transfusions is the platelet transfusion refractoriness. The study and management of this complication is often disappointing. In summary, although it is a widespread practice, platelet transfusion has still many controversial and unknown issues. The objective of this article is to review the current evidence on platelet transfusion practices, focusing on the controversial issues and challenges.

[Donors selection and retrieval of units in an umbilical cord blood bank]. / Selección de donantes y recogida de las unidades en un banco de sangre de cordón umbilical.

BACKGROUND AND OBJECTIVE: Umbilical cord blood (UCB) contains hematopoietic stem cells that can be used as an alternative to bone marrow transplantation in certain cases. This study was designed to investigate the influence of obstetric, neonatal and collection factors on the hematopoietic content of UCB donations. MATERIAL AND METHOD: A total of 391 consecutive maternal-neonatal pairs were evaluated during the prepartum period in the maternity ward at La Fe University Hospital. Maternal, neonatal and collection factors influencing cord blood quality measured as volume, total nucleated cells count, CD34+ cells and colony forming units were analyzed in 2,000 UCB collections. RESULTS: 32.5% of UCB potential donors were excluded, mainly due to obstetrical reasons. Among the collected units, 56% were discarded before cryopreservation, mainly due to low cell counts. In the multivariate analysis, placental weight was a predictor variable for total nucleated cells, CD34+ cells and colony forming units, while the mode of collection influenced the total nucleated cells and CD34+ cell counts. CONCLUSIONS: The collection of UCB units before placental delivery (using the birth weight as an estimation of the placental weight) could be added to standard cord blood donors criteria in order to improve the bank efficiency.

Selección de donantes y recogida de las unidades en un banco de sangre de cordón umbilical / Donors selection and retrieval of units in an umbilical cord blood bank

Fundamento y objetivo: El contenido cualitativo y cuantitativo de la fracción celular es el factor principal que limita el uso clínico de progenitores hematopoyéticos de sangre de cordón umbilical (SCU). Con el fin de optimizar la calidad de la SCU, se ha llevado a cabo un estudio sobre los criterios de selección de donantes en nuestro entorno geográfico, comparando además diferentes métodos de recogida. Material y método: Se analizaron 391 donaciones potenciales de SCU en la maternidad del Hospital Universitario La Fe. Se evaluaron diversos factores obstétricos relativos a 2.000 unidades de SCU. También se analizó el valor del peso placentario y del recién nacido. Resultados: Se excluyó al 32,5% de las donantes potenciales, principalmente por factores obstétricos. El 56% de las unidades recogidas se rechazó antes de la criopreservación, debido al insuficiente número de células. En el análisis multivariante se demostró que el peso de la placenta fue el único factor predictivo que influyó en la cantidad de células nucleadas totales, células CD34+ y unidades formadoras de colonias, mientras que el modo de recogida también influyó en las cifras de células nucleadas totales y células CD34+. Conclusiones: Nuestro estudio demuestra que, teniendo en cuenta diversos factores obstétricos previamente a la recogida de SCU, se puede optimizar su contenido en progenitores hematopoyéticos. La recogida intraútero es, según nuestros resultados, la mejor estrategia para obtener unidades de SCU eficientemente

Background and objective: Umbilical cord blood (UCB) contains hematopoietic stem cells that can be used as an alternative to bone marrow transplantation in certain cases. This study was designed to investigate the influence of obstetric, neonatal and collection factors on the hematopoietic content of UCB donations. Material and method: A total of 391 consecutive maternal-neonatal pairs were evaluated during the prepartum period in the maternity ward at La Fe University Hospital. Maternal, neonatal and collection factors influencing cord blood quality measured as volume, total nucleated cells count, CD34+ cells and colony forming units were analyzed in 2,000 UCB collections. Results: 32.5% of UCB potential donors were excluded, mainly due to obstetrical reasons. Among the collected units, 56% were discarded before cryopreservation, mainly due to low cell counts. In the multivariate analysis, placental weight was a predictor variable for total nucleated cells, CD34+ cells and colony forming units, while the mode of collection influenced the total nucleated cells and CD34+ cell counts. Conclusions: The collection of UCB units before placental delivery (using the birth weight as an estimation of the placental weight) could be added to standard cord blood donors criteria in order to improve the bank efficiency